Katzung, B. G., Masters, S. B., & Trevor, A. J. (2009, January 1). Basic and Clinical Pharmacology.
Gotto, A. M. Jr, Opie, & B. J. Gersh. (n.d.). Lipid-Modifying Antiatherosclerotic Drugs: Drugs for the Heart (8th ed.). Elsevier Saunders.
Briggs, G. G., & R. K. (n.d.). A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation (10th ed.). Wolters Kluwer Health.
Fenofibrate: Uses, interactions, mechanism of action | DrugBank Online. (n.d.). DrugBank. https://go.drugbank.com/drugs/DB01039
Fenofibrate 160mg Tablets - Summary of Product Characteristics (SmPC) - (emc). (n.d.-b). https://www.medicines.org.uk/emc/product/5267/smpc#:~:text=Fenofibrate%20160%20mg%20Tablets%20are,is%20contraindicated%20or%20not%20tolerated.
McKeage, K., & Keating, G. M. (2011). Fenofibrate: a review of its use in dyslipidaemia. Drugs, 71, 1917-1946.
Rosenson, R. S. (2008). Fenofibrate: treatment of hyperlipidemia and beyond. Expert review of cardiovascular therapy, 6(10), 1319-1330.
FIELD Study Investigators. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849-1861.
Keech, A. C., Mitchell, P., Summanen, P. A., O'Day, J., Davis, T. M., Moffitt, M. S., ... & Colman, P. G. (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697.